Summary
The objective of this study was to assess the change in healthcare resource utilisation and costs related to the initiation of risperidone therapy in patients with chronic schizophrenia. The study design used a retrospective cohort and linked data from 5 databases (patient, prescription drug, hospital, physician and mental health services) within the province of Saskatchewan. Study participants included all those patients who were registered in the Saskatchewan Health Linkable Data Files and received at least 1 prescription for risperidone between 1 July 1993 and 31 December 1993. In order to receive risperidone in Saskatchewan, patients needed to have failed or become intolerant to previous antipsychotic therapy. Utilisation information from the databases was collected for equivalent periods, in this case an average of 10 months, before and after initiation of risperidone.
Results were as follows: hospital admissions decreased by 60.3%, length of hospital stay decreased by 58.2%, and physician visits decreased by 22.3%, after initiation of risperidone. There was also a slight reduction in visits to mental health services. The cost of antipsychotic medication increased during risperidone treatment; however, when all costs were added up, there was an estimated annual cost saving of $Can7925/patient/year after initiation of risperidone. Such results need to be interpreted in the light of possible mitigating effects operative in longitudinal studies of schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S89–95
Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psych 1994; 39 9 Suppl.: S46–52
Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–35
Borison RL, Pathiraja AP, Diamond BL, et al. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213–8
Remington G. Clinical consideration in the use of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S96–100
Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17: 475–81
Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39 Suppl. 2: S65–9
Wyatt R. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17(2): 325–51
Kane J, Marder S. Psychopharmacologic treatment of schizophrenia. Sehizophr Bull 1993; 19(2): 113–28
Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 Suppl. 25; 18–21
Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26
Strand LM, Downey W. Health databases in Saskatchewan. Strom BL, editor. Pharmacoepidemiology. 2nd ed. West Sussex, UK: John Wiley and Sons Ltd, 1994
Saskatchewan Health Prescription Drug Services Formulary. 41st ed. Regina Saskatchewan: 1995
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
Government of Saskatchewan. Saskatchewan Health Annual Statistical Report 1992–93. Regina: Saskatchewan
Government of Saskatchewan. Saskatchewan Health Annual Statistical Report 1993–94. Regina: Saskatchewan
Reid WH. The treatment of psychosis: resetting the drug cost ‘thermostat’. J Clin Psychiatry 1994; 55 9 Suppl. B: 166–8
Chiles JA, Davidson P, McBride D. Effects of clozapine on the use of seclusion and restraint. Hosp Community Psychiatry 1994; 45: 269–71
Arnold SE, Gur RE, Shapiro RM, et al. Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am J Psychiatry 1995; 152(5): 731–7
Hatfield AB, Spaniol L, Zipple AM. Expressed emotion: a family perspective. Schizophr Bull 1987; 13(2): 221–6
Bellack AS, Mueser KJ, Psychosocial treatment for schizophrenia. Schizophr Bull 1990; 19(2): 142–62
Hogarty GE. Prevention of relapse in chronic schizophrenia patients. J Clin Psychiatry 1993; 3 Suppl.: 18–23
Harding CM, Brookes G, Ashikaga P, et al. The Vermont longitudinal study of persons with severe mental illness. I. Methodology, study sample and overall status 32 years later. Am J Psychiatry 1987; 144: 718–26
Harding CM, Brookes G, Ashikaga P, et al. The Vermont longitudunal study of persons with severe mental illness. II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987; 144: 727–35
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Albright, P.S., Livingstone, S., Keegan, D.L. et al. Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy. Clin. Drug Invest. 11, 289–299 (1996). https://doi.org/10.2165/00044011-199611050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199611050-00005